2019
Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics
Bitton G, Rom V, Hadelsberg U, Raz I, Cengiz E, Weinzimer S, Tamborlane WV. Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics. Journal Of Diabetes Science And Technology 2019, 13: 1123-1128. PMID: 31067999, PMCID: PMC6835184, DOI: 10.1177/1932296819842151.Peer-Reviewed Original ResearchConceptsInjection siteGlucose levelsSerum glucoseSubcutaneous depotMultiple daily insulin injectionsOvernight glucose levelsDaily insulin injectionsBlood glucose controlType 1 diabetesSensor glucose levelsInsulin infusion rateDL increaseInsulin glargineSerum insulinGlucose controlMDI therapyInsulin injectionsInsulin concentrationsPharmacodynamic studiesInfusion rateSkin warmingSeparate daysControl dayRate of absorptionRandom order
2016
Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Tichy EM, Weyman K, Weinzimer SA, Tamborlane WV, Sherr JL. Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study. Diabetes Technology & Therapeutics 2016, 18: 794-799. PMID: 27996320, PMCID: PMC5178000, DOI: 10.1089/dia.2016.0311.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBlood GlucoseCross-Over StudiesDiabetes Mellitus, Type 1ExerciseFemaleHumansHypoglycemic AgentsInsulinMaleSnacksYoung AdultConceptsClosed-loop insulin deliveryPlasma glucoseEnd of exercisePG levelsExercise studiesInsulin deliveryExercise periodCL insulin deliveryExercise-induced loweringType 1 diabetes subjectsExercise-induced reductionRecovery periodBrisk treadmillDL increaseRescue treatmentDiabetes subjectsInsulin infusionExerciseInsulinSimilar differencesVisitsCL controlDeliveryGlucosePeriodGlucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care 2016, 39: 555-562. PMID: 26884472, PMCID: PMC4806770, DOI: 10.2337/dc15-1606.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAdolescentBlood GlucoseChildChild, PreschoolCohort StudiesCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugDouble-Blind MethodDrug-Related Side Effects and Adverse ReactionsFemaleGlucagonHumansHypoglycemiaInjections, IntramuscularInsulinMaleNauseaPowdersConceptsIntramuscular glucagonType 1 diabetesIntranasal dosesIntranasal glucagonYounger cohortsWeight-based doseMin of dosingTreatment of hypoglycemiaDose-response relationshipTransient nauseaDl riseSevere hypoglycemiaGlucagon levelsIntranasal doseClinical centersPlasma glucosePharmacodynamic studiesHospital settingGlucagon preparationPotential efficacyGlucagonType 1Adverse effectsCohortAge range
2015
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2015, 39: 264-270. PMID: 26681725, PMCID: PMC4722945, DOI: 10.2337/dc15-1498.Peer-Reviewed Original ResearchConceptsInsulin-induced hypoglycemiaType 1 diabetesIntramuscular glucagonIntranasal glucagonSevere hypoglycemiaPlasma glucoseCrossover noninferiority trialTreatment of hypoglycemiaLoss of consciousnessReal-world managementDosing visitsGlucagon responseIntravenous insulinNoninferiority studyGlucagon administrationClinical centersFacial discomfortNoninferiority trialHospital settingGlucagon preparationHypoglycemiaTherapeutic insulinGlucagonType 1Mean timeImproved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes
Raz I, Bitton G, Feldman D, Alon T, Pfutzner A, Tamborlane WV. Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes. Journal Of Diabetes Science And Technology 2015, 9: 639-643. PMID: 25883166, PMCID: PMC4604546, DOI: 10.1177/1932296815578881.Peer-Reviewed Original ResearchConceptsRapid-acting insulin analoguesType 2 diabetesMeal tolerance testPlasma insulin levelsInsulin analoguesInsulin levelsGlucose excursionsInjection siteInsulin absorptionType 2 diabetic patientsPostmeal glucose excursionsStandardized liquid mealPostprandial glucose excursionsTime-action profilePostprandial glucose controlInsulin therapyDiabetic patientsGlucose controlLiquid mealOvernight fastInsulin aspartTolerance testPostprandial hyperglycemiaPremeal bolusesPremeal injections
2014
Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double‐blind and open‐label cross‐over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况:赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验
Tamborlane WV, Renard E, Wadwa RP, Blevins T, Jacober SJ, Liu R, D'Souza DN, Rees TM. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double‐blind and open‐label cross‐over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况:赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验. Journal Of Diabetes 2014, 7: 270-278. PMID: 24734891, DOI: 10.1111/1753-0407.12162.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood GlucoseBlood Glucose Self-MonitoringChinaCross-Over StudiesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Double-Blind MethodFemaleFollow-Up StudiesHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulin AspartInsulin Infusion SystemsInsulin LisproMalePostprandial PeriodPrognosisRisk FactorsConceptsContinuous subcutaneous insulin infusionSelf-monitoring blood glucoseTreatment periodCross-over designBlood glucoseDay 6Insulin aspartInsulin lisproMean total daily insulin doseTotal daily insulin doseTotal hypoglycemia rateDaily insulin dosePrimary efficacy measureType 1 DMMean blood glucoseSubcutaneous insulin infusionType 1 diabetesHypoglycemia ratesInsulin doseRandomized trialsEfficacy measuresSMBG profilesInsulin infusionDay 1Two-treatment
2012
Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device
Cengiz E, Weinzimer SA, Sherr JL, Tichy E, Martin M, Carria L, Steffen A, Tamborlane WV. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatric Diabetes 2012, 14: 168-173. PMID: 23107353, PMCID: PMC3572265, DOI: 10.1111/pedi.12001.Peer-Reviewed Original ResearchConceptsPlasma insulin levelsInsulin actionInsulin levelsAspart insulinRapid-acting insulin analoguesPhysiologic insulin actionClosed-loop insulin deliveryPostprandial glucose excursionsEuglycemic clamp techniqueIp activationTime-action profileType 1 diabetesWarming devicesEuglycemic clamp procedureBolus doseGlucose excursionsPharmacodynamic profileClamp procedurePeak actionInfusion siteBlood flowInsulin analoguesClamp techniqueInsulin absorptionInsulin bolusEffect of Insulin Feedback on Closed-Loop Glucose Control: A Crossover Study
Ruiz JL, Sherr JL, Cengiz E, Carria L, Roy A, Voskanyan G, Tamborlane WV, Weinzimer SA. Effect of Insulin Feedback on Closed-Loop Glucose Control: A Crossover Study. Journal Of Diabetes Science And Technology 2012, 6: 1123-1130. PMID: 23063039, PMCID: PMC3570847, DOI: 10.1177/193229681200600517.Peer-Reviewed Original ResearchConceptsBG excursionsPostprandial hypoglycemiaBG levelsMeal-related glucose excursionsInsulin deliveryLate postprandial hypoglycemiaTotal insulin deliveryOverall glycemic controlOccurrence of hypoglycemiaClosed-loop glucose controlMean BG levelClosed-loop insulin delivery systemAverage BG levelsBlood glucose responseSeparate admissionsGlycemic controlCrossover studyGlucose controlHypoglycemic eventsGlucose excursionsInsulin delivery systemsGlucose riseBG controlInsulin feedbackManual boluses
2011
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA, . Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase. Diabetes Care 2011, 34: 2403-2405. PMID: 21933908, PMCID: PMC3198292, DOI: 10.2337/dc11-1248.Peer-Reviewed Original Research
2005
Impact of Exercise on Overnight Glycemic Control in Children with Type 1 Diabetes Mellitus
Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, Wysocki T, Weinzimer SA, Buckingham BA, Kollman C, Xing D, Ruedy KJ. Impact of Exercise on Overnight Glycemic Control in Children with Type 1 Diabetes Mellitus. The Journal Of Pediatrics 2005, 147: 528-534. PMID: 16227041, PMCID: PMC2258153, DOI: 10.1016/j.jpeds.2005.04.065.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseChildCircadian RhythmCohort StudiesCross-Over StudiesDiabetes Mellitus, Type 1ExerciseFemaleHumansHypoglycemiaMaleConceptsGlucose levelsExercise nightsOvernight hypoglycemiaType 1 diabetes mellitusOvernight glycemic controlClinical Research CenterRisk of hypoglycemiaEffects of exerciseImpact of exerciseBlood glucose levelsAfternoon exerciseDiabetes mellitusGlycemic controlInsulin dosesSedentary dayExercise dayExercise sessionsDiabetes managementHypoglycemiaSeparate daysClinical sitesType 1Central laboratoryMellitusT1DM